Healthcare [ 13/13 ] | Biotechnology [ 127/164 ]
NASDAQ | Common Stock
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States.
The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction.
In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention.
Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 15, 24 | -1.01 Decreased by -14.77% | -1.20 Increased by +15.83% |
| Mar 12, 24 | -1.31 Decreased by -167.35% | -1.36 Increased by +3.68% |
| Nov 9, 23 | -1.28 Decreased by -52.38% | -1.37 Increased by +6.57% |
| Aug 10, 23 | -1.17 Decreased by -387.50% | -1.08 Decreased by -8.33% |
| May 9, 23 | -0.88 Increased by +10.20% | -0.94 Increased by +6.38% |
| Mar 13, 23 | -0.49 Increased by +31.94% | -0.69 Increased by +28.99% |
| Nov 9, 22 | -0.84 Decreased by -10.53% | -0.97 Increased by +13.40% |
| Aug 11, 22 | -0.24 Decreased by -172.73% | -0.59 Increased by +59.32% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 27.61 M Increased by +1.00 K% | -35.73 M Decreased by -63.26% | Decreased by -129.39% Increased by +85.22% |
| Dec 31, 23 | 13.08 M Increased by +30.76% | -41.90 M Decreased by -220.40% | Decreased by -320.45% Decreased by -145.03% |
| Sep 30, 23 | 1.87 M Increased by +N/A% | -39.15 M Decreased by -73.91% | Decreased by -2.09 K% Decreased by N/A% |
| Jun 30, 23 | 15.28 M Increased by 0.00% | -31.42 M Decreased by -401.82% | Decreased by -205.69% Decreased by -401.82% |
| Mar 31, 23 | 2.50 M Increased by +363.82% | -21.89 M Decreased by -8.14% | Decreased by -875.44% Increased by +76.68% |
| Dec 31, 22 | 10.00 M Increased by +2.86 K% | -13.08 M Increased by +11.94% | Decreased by -130.78% Increased by +97.02% |
| Sep 30, 22 | 0.00 Decreased by -100.00% | -22.51 M Decreased by -43.41% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 15.28 M Decreased by -30.61% | -6.26 M Decreased by -198.69% | Decreased by -40.99% Decreased by -242.23% |